Preview

Medical Immunology (Russia)

Advanced search

ANTI-TUMOR ACTIVITY OF DENDRITIC CELLS IN HEALTHY DONORS AND PATIENTS WITH BRAIN TUMORS

https://doi.org/10.15789/1563-0625-2010-3-199-206

Abstract

In present work, a comparative analysis of cytostatic and cytotoxic activity of IL-4 and IFNα-induced dendritic cells (IL-4- and IFN-DCs) has been performed in healthy donors and patients with brain tumors. Cytostatic activity was evaluated, as a capacity of DCs to inhibit growth of NK-resistant HEp-2 and A-549 tumor cell lines, whereas cytotoxic activity was measured by assessment of HEp-2 lysis. As compared with IL4-DC, IFN-DCs from healthy donors displayed a more pronounced cytostatic effect and similar cytotoxic activity against HEp-2 cells. In the patients with brain tumors, IFN-DCs were characterized by decreased cytotoxic activity. Meanwhile, DCs from the patients with malignant gliomas virtually did not exhibit a cytotoxic potential, whereas IFN-DCs from the patients with benign brain tumors retained their cytotoxic properties. A comparative study has shown that, in contrast to healthy donors, IFN-DCs from the patients with either malignant or benign brain tumors did not inhibit HEp-2 proliferation. The loss of DC-mediated cytostatic activity was not associated with decrease of CD123+ DCs (known as cells with maximal tumor-inhibitory potential), and, most likely, it resulted from functional changes in IFN-DC populations.

About the Authors

E. R. Chernykh
НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation


O. Yu. Leplina
НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation


T. V. Tyrinova
НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation


M. A. Tikhonova
НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation


V. V. Stupak
ФГУ НИИ травматологии и ортопедии Росмедтехнологий, г. Новосибирск
Russian Federation


S. V. Mishinov
ФГУ НИИ травматологии и ортопедии Росмедтехнологий, г. Новосибирск
Russian Federation


I. V. Pendyurin
ФГУ НИИ травматологии и ортопедии Росмедтехнологий, г. Новосибирск
Russian Federation


A. A. Ostanin
НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation


References

1. Черных Е.Р., Леплина О.Ю., Ступак В.В., Пендюрин И.В., Никонов С.Д., Тихонова М.А., Останин А.А. Клеточные технологии в лечении злокачественных глиом головного мозга//Клеточные технологии. Теоретические и прикладные аспекты. -Новосибирск: Наука, 2009. -С. 240-276.

2. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y., Pulendran B., Palucka K. Immunobiology of dendritic cells//Annu Rev Immunol. -2000. -Vol. 18. -P. 767-811.

3. Becker Y. Dendritic cell activity against primary tumors: an overview//In Vivo. -1993. -Vol. 7. -P. 187-191.

4. Chaperot L., Blum A., Manches O., Lui G., Angel J., Molens J-P., Plumas J. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells//J. Immunol. -2006. -Vol. 176. -P. 248-255.

5. Chapoval A.I., Tamada K., Chen L. In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells//Blood. -2000. -Vol. 95. -P. 2346-2351.

6. Chauvin C., Josien R. Dendritic cells as killers: mechanistic aspects and potential roles// J. Immunol. -2008. -Vol. 18. -P. 11-16.

7. Della Bella S., Nicola S., Riva A., Biasin M., Clerici M., Villa M.L. Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-α//J. Leuk Biol. -2004. -Vol. 75. -P. 106-116.

8. Ehtesham M.P., Kabos M.A., Gutierrez K., Samoto K.L., Black J., Yu S. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats//J. Immunother. -2003. -Vol. 26. -P. 107-116.

9. Fanger N.A., Maliszewski C.R., Schooley K., Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)//J. Exp. Med. -1999. -Vol. 190. -P. 1155-1164.

10. Jun S., Ikeda K., Maeda Y., Shinagawa K., Ohtsuka A., Yamamura H., Tanimoto M. Identification of CD123+ myeloid dendritic cells as anearly-stage immature subset with strong tumoristatic potential//Cancer Letters. -2008. -Vol. 270. -P. 19-29.

11. Korthals M., Safaian N., Kronenwett R., Maihfer D., Schott M., Papewalis C., Blanco E.D., Winter M., Czibere A., Haas R., Kobbe G., Fenk R. Monocyte derived dendritic cells generated by IFNα acquire mature dendritic and natural killer cell properties as shown by gene expression analysis// J. Translational Med. -2007. -Vol. 5. -P. 46-57.

12. Larmonier K., Fraszczak J., Lakomy D., Bonnotte B., Katsanis E. Killer dendritic cells and their potential for cancer immunotherapy//Cancer Immunol & Immunother. -2009. -Vol. 59. -P. 1-11.

13. Liu S., Yu Y., Zhang M., Wang W., Cao X. The involvement of TNF-alpha-related apoptosis inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells// J. Immunol. -2001. -Vol. 166. -P. 5407-5415.

14. Manna P.P., Mohanakumar T. Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro//J. Leuk Biol. -2002. -Vol. 72. -P. 312-320.

15. Melief C.J. Cancer immunotherapy by dendritic cells//Immunity. -2008. -Vol. 29. -P. 372-383.

16. Santini S., Pucchini T., Lapenta C., Parlato S., Logozzi M., Belardelli F. A new type 1 IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells//Stem cells. -2003. -Vol. 21. -P. 357-362.

17. Shin J.Y., Lee C.D. Kang J.S., Chung E., Lee Y., Seo S.Y., Lee S.Y., Baek S.Y., Kim B.S., Kim J.B., Yoon S. Anti-tumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model//Histol. Histopathol. -2003. -Vol. 18. -P. 435-447.

18. Tong Y., Song W., Crystal R.G. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors//Cancer Res. -2001. -Vol. 61. -P. 7530-7535.

19. Vanderheyde N., Vandenabeele P., Goldman M., Willems F. Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells//Immunol Lett. -2004. -Vol. 91. -P. 99-101.

20. Vidalain P.O., Azocar O., Yagita H., Rabourdin-Combe C., Servet-Delprat C. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand// J. Immunol. -2001. -Vol. 167, N 7. -P. 3765-3772.

21. Wang M., Shi J., Wan Y., Li J., Yuan Y. A subset of myeloid dendritic cells derived from peripheral blood monocytes represented a predominant subset characterized by their potential tumor-inhibiting activity//In Vitro Cell. Dev. Biol.-Animal. -2009. -Vol. 45. -P. 398-404.

22. Wesa A.K., Storkus W.J. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer//Cell Death Differ. -2008. -Vol. 15. -P. 51-57.


Review

For citations:


Chernykh E.R., Leplina O.Yu., Tyrinova T.V., Tikhonova M.A., Stupak V.V., Mishinov S.V., Pendyurin I.V., Ostanin A.A. ANTI-TUMOR ACTIVITY OF DENDRITIC CELLS IN HEALTHY DONORS AND PATIENTS WITH BRAIN TUMORS. Medical Immunology (Russia). 2010;12(3):199-206. (In Russ.) https://doi.org/10.15789/1563-0625-2010-3-199-206

Views: 980


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)